Treatment Information

Back

Mesothelioma treatment details. Biologic therapy.

Azienda Ospedaliera Universitaria Senese, Siena, Italy.

Survival: monthsCountry:Italy
Toxiciy Grade:4City/State/Province:Siena
Treatments:Biologic therapyHospital:Azienda Ospedaliera Universitaria Senese
Drugs:Journal:Link
Date:Oct 2013

Description:

Patients:
This phase 2 study involved 29 advanced malignant mesothelioma patients who had received previous platinum-based chemotherapy. The median patient age was 64 years and 72% were male.

Treatment:
Patients were treated with the biologic therapy agent called tremelimumab, a monoclonal antibody that inhibits the CTLA-4 protein and enhances the anti-tumor immune response.

Toxicities:
The most severe toxicities were grade 4 liver toxicity. Grade 3 gastrointestinal and nerve toxicities were also reported.

Results:
The median overall survival was 10.7 months.

Support:
This study was partially supported by Pfizer.

Correspondence: Dr. Michele Maio; email: [email protected]



Back